STATE STREET CORP - IMMUNOCELLULAR THERAPEUTICS ownership

Quarter-by-quarter ownership
STATE STREET CORP ownership history of IMMUNOCELLULAR THERAPEUTICS
ValueSharesWeighting
Q3 2016$4,000
-42.9%
29,1730.0%0.00%
Q2 2016$7,000
-12.5%
29,1730.0%0.00%
Q1 2016$8,000
-27.3%
29,1730.0%0.00%
Q4 2015$11,000
-8.3%
29,1730.0%0.00%
Q3 2015$12,000
-14.3%
29,1730.0%0.00%
Q2 2015$14,0000.0%29,1730.0%0.00%
Q1 2015$14,000
-36.4%
29,1730.0%0.00%
Q4 2014$22,000
-24.1%
29,173
-10.4%
0.00%
Q3 2014$29,000
-19.4%
32,5730.0%0.00%
Q2 2014$36,000
-10.0%
32,5730.0%0.00%
Q1 2014$40,000
-96.5%
32,573
-94.6%
0.00%
Q4 2013$1,130,000
+1007.8%
605,478
+1430.0%
0.00%
Q3 2013$102,000
+24.4%
39,573
-6.4%
0.00%
Q2 2013$82,00042,2730.00%
Other shareholders
IMMUNOCELLULAR THERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
Callan Capital, LLC 70,000$65,0000.02%
Wellington Shields Capital Management, LLC 51,000$47,0000.01%
Ifrah Financial Services, Inc. 18,500$17,0000.01%
CHELSEA COUNSEL CO 28,000$26,0000.01%
DRW Securities, LLC 120,000$111,0000.01%
TUDOR INVESTMENT CORP ET AL 66,303$61,0000.00%
OPPENHEIMER & CO INC 107,000$99,0000.00%
First Allied Advisory Services, Inc. 45,000$42,0000.00%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 70,000$65,0000.00%
GROUP ONE TRADING, L.P. 160,103$148,0000.00%
View complete list of IMMUNOCELLULAR THERAPEUTICS shareholders